WASHINGTON, D.C. — The U.S. Food and Drug Administration has released draft guidance that could shorten development timelines for gene therapies by allowing drugmakers to make greater use of existing scientific and regulatory data when seeking approval for new treatments.
The guidance, issued last week, outlines how sponsors developing gene therapies that use genome editing in human somatic cells may leverage publicly available information and prior knowledge—including manufacturing, nonclinical and clinical data—to support regulatory submissions.
The initiative is aimed at reducing duplication in product development while maintaining existing safety and efficacy standards, a move that could lower development costs and accelerate access to treatments for patients with rare and life-threatening diseases.
The FDA said the guidance would apply broadly across the cell and gene therapy sector and complements other recent agency efforts to establish clearer regulatory pathways for genome-editing technologies.
Karim Mikhail, acting director of the FDA’s Center for Biologics Evaluation and Research, said the agency is seeking to accelerate development without reducing scientific rigor.
“By providing information on how companies may build on what is already known, we are accelerating innovation without compromising the rigorous scientific standards that patients and the public depend on,” Mikhail said.
The guidance works alongside the FDA’s Plausible Mechanism Framework and a separate draft guidance on evaluating off-target genome-editing risks through next-generation sequencing. Together, the documents are intended to provide developers with a more defined regulatory framework for advancing cell and gene therapy programs.
The agency emphasized that companies seeking to rely on prior data must provide scientific justification demonstrating that the information is applicable to their specific product and development program.
Vijay Kumar, acting director of the Office of Therapeutic Products, said the approach is designed to improve efficiency while preserving regulatory standards.
“Leveraging prior knowledge does not mean lowering the bar; it means raising our collective efficiency while maintaining the highest standards of safety and efficacy,” Kumar said.
The FDA is encouraging developers to engage with regulators early in the development process through programs such as INTERACT and pre-investigational new drug meetings to discuss proposed strategies.
The draft guidance is open for public comment. Stakeholders will have 90 days following publication in the Federal Register to submit feedback through Regulations.gov before the agency considers finalizing the document.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.